PRO MEDICUS LIMITED (PME)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PME

PME - PRO MEDICUS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.01
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Pro Medicus is an imaging IT company providing a range of radiology software and services, medical accounting and clinical reporting to the health care sector. Founded in 1983, the company listed on the ASX in 2000.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$185.39

25 Jun
2026

6.400

OPEN

$180.00

3.58%

HIGH

$186.04

363,026

LOW

$179.01

TARGET
$218.667 17.9% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
PME: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx 254.0 195.2 xxx
DPS (cps) xxx 69.0 93.9 xxx
EPS Growth xxx 100.0% - 23.1% xxx
DPS Growth xxx 25.5% 36.1% xxx
PE Ratio xxx N/A 100.5 xxx
Dividend Yield xxx N/A 0.5% xxx
Div Pay Ratio(%) xxx 27.2% 48.1% xxx

Dividend yield today if purchased 3 years ago: 0.86%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.35

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 07/09 - ex-div 37.00c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx254.0
DPS All xxxxxxxxxxxxxxx69.0
Sales/Revenue xxxxxxxxxxxxxxx261.7 M
Book Value Per Share xxxxxxxxxxxxxxx431.6
Net Operating Cash Flow xxxxxxxxxxxxxxx136.5 M
Net Profit Margin xxxxxxxxxxxxxxx101.40 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx74.97 %
Return on Invested Capital xxxxxxxxxxxxxxx74.65 %
Return on Assets xxxxxxxxxxxxxxx55.93 %
Return on Equity xxxxxxxxxxxxxxx74.97 %
Return on Total Capital xxxxxxxxxxxxxxx55.06 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx71.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx251 M
Price To Book Value xxxxxxxxxxxxxxx47.13

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx8.7 M
Capex % of Sales xxxxxxxxxxxxxxx3.32 %
Cost of Goods Sold xxxxxxxxxxxxxxx51 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx15 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx189 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

30/04/2026

1

Overweight

$200.00

7.88%

Morgan Stanley notes leading ASX software incumbents are not only exposed to AI-driven disruption, but are also well positioned to harness AI to their advantage.

In many cases, these firms may be better placed than new entrants, the analysts suggest, given their access to proprietary data, deep vertical expertise, scale and established distribution networks.

The broker introduces its Moat Framework, comprising 10 factors used to assess which companies can sustain differentiated value in an AI-driven landscape. This considers those best positioned to adapt, and where competitive advantages are most at risk of erosion.

Morgan Stanley's central conclusion is that while AI is lowering the cost of software development, it does not render all software free, nor does it eliminate the need for third-party vendors.

From among the broker's coverage, key preferred exposures include REA Group, WiseTech Global, CAR Group, Xero and Pro Medicus.

Least preferred are Appen, Airtasker and Megaport.

Overweight retained for Pro Medicus. Target $200. Industry View: Attractive.

FORECAST
Morgan Stanley forecasts a full year FY26 dividend of 55.60 cents and EPS of 139.10 cents.
Morgan Stanley forecasts a full year FY27 dividend of 73.60 cents and EPS of 184.10 cents.

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

13/05/2026

1

Buy

$168.62

-9.05%

Canaccord Genuity maintains a Buy rating for Pro Medicus and reduces the target price to $168.62 from $180.82 following a review of the company's valuation relative to sector-wide multiple compression.

Revenue forecasts have been revised down by -8% for FY26 and -11% for FY27 to reflect lower data migration revenue and a higher AUD:USD exchange rate headwind.

The broker notes underlying fundamentals remain exceptional, with the business expected to deliver growth exceeding 20% on both the top and bottom lines despite negative sector sentiment.

Large contract wins yet to materialise in the profit and loss statement underpin significant earnings momentum for FY27 and FY28.

Mispricing is evident as market volatility masks the value of businesses with high excess cash returns, according to the report.
Access Extra Coverage Research History >

PME STOCK CHART

FNArena News on PME

Latest Medical Equipment & Devices News

1
Shortages Chip Away At ResMed’s Big Break

Mar 30 2022 - Australia
2
Opportunity for Fisher & Paykel Healthcare

Mar 25 2022 - Australia
3
Distribution Anxiety For Nanosonics

Feb 10 2022 - Australia
4
Brokers Awake To ResMed’s Potential

Jan 31 2022 - Australia
5
Covid Benefits F&P Healthcare, For Now

Dec 06 2021 - Australia
6
Will Shortages Limit Upside For ResMed?

Nov 01 2021 - Australia
7
Nanosonics Unveils Its New Product

Aug 26 2021 - Australia
8
Pro Medicus: Opportunity Awaits

Aug 24 2021 - Technicals
9
Breakout For Cochlear

Aug 10 2021 - Technicals
10
Will ResMed’s Market Share Gains Last?

Aug 09 2021 - Australia